55 related articles for article (PubMed ID: 10173030)
1. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?
Hackshaw A; Sweetenham J; Knight A
Br J Cancer; 2004 Apr; 90(7):1302-5. PubMed ID: 15054445
[TBL] [Abstract][Full Text] [Related]
2. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy.
Beard SM; Wall L; Gaffney L; Sampson F
Pharmacoeconomics; 2004; 22(4):207-24. PubMed ID: 14974872
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
Esser M; Brunner H
Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.
Dranitsaris G
Pharmacoeconomics; 1999 Oct; 16(4):343-53. PubMed ID: 10623363
[TBL] [Abstract][Full Text] [Related]
5. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.
Repetto L; Biganzoli L; Koehne CH; Luebbe AS; Soubeyran P; Tjan-Heijnen VC; Aapro MS
Eur J Cancer; 2003 Nov; 39(16):2264-72. PubMed ID: 14556916
[TBL] [Abstract][Full Text] [Related]
6. The role of myelopoietic growth factors in managing cancer in the elderly.
Balducci L; Carreca I
Drugs; 2002; 62 Suppl 1():47-63. PubMed ID: 12479594
[TBL] [Abstract][Full Text] [Related]
7. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
Dranitsaris G; Altmayer C; Quirt I
Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
[TBL] [Abstract][Full Text] [Related]
8. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
9. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma.
Rubino C; Laplanche A; Patte C; Michon J
J Natl Cancer Inst; 1998 May; 90(10):750-5. PubMed ID: 9605644
[TBL] [Abstract][Full Text] [Related]
10. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
[TBL] [Abstract][Full Text] [Related]
11. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
[TBL] [Abstract][Full Text] [Related]
12. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
[TBL] [Abstract][Full Text] [Related]
13. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.
Torrance GW; Blaker D; Detsky A; Kennedy W; Schubert F; Menon D; Tugwell P; Konchak R; Hubbard E; Firestone T
Pharmacoeconomics; 1996 Jun; 9(6):535-59. PubMed ID: 10160481
[TBL] [Abstract][Full Text] [Related]
14. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs.
Posnett J; Jan S
Health Econ; 1996; 5(1):13-23. PubMed ID: 8653189
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]